AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Stock picking may pay off in certain market conditions and for investors with time and expertise. Learn factors to consider before deviating from index funds.
26,454 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Could oil trend toward $60 a barrel by 2027? This article analyzes the scenario, the forces at play, and concrete sto...
Tech weakness and memory-chip swings are weighing on major indexes this June. Learn what’s driving the move and how t...
Stocks hover near the flat line as a cooler payrolls report shapes trading. The S&P 500 stalls while investors assess...
SpaceX dazzled investors at IPO, but the price soon drifted below debut. This article shows how a $10,000 investment ...
IonQ posted quarterly results that beat expectations, triggering a notable after-hours rally. Analysts warn the stock...
Sunrun’s stock tumbled on a day of mixed signals: strong quarterly revenue but cautious guidance for 2026. This artic...
A headline about Palantir and a high-stakes defense AI plan could reshape risk and opportunity. This guide breaks dow...
Defiance’s 2X inverse ETF tied to SMCI confronts a classic risk now that SMCI has reported after hours. The fund’s da...
A major hedge fund slashed its stake in Structure Therapeutics, prompting questions about the future path for GPCR-fo...
Analysts often set price targets to frame potential moves for AI stocks. This article breaks down how those targets a...
Travel demand is returning, but 2026 presents varied challenges for United Airlines. This guide breaks down the Unite...